Incannex Healthcare has confirmed that its PsiGAD1 clinical trial has achieved its interim milestone of 29 patients completing primary endpoint assessments.
A social poll by the healthy living and aging platform, Goldster, revealed that over 65s are more open to trying microdosing than those under the age...
Algernon Pharmaceuticals has announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation...
Psychedelics are being touted as a potential breakthrough in the area of mental health treatment.
Field Trip Health & Wellness has launched Field Trip Online Therapy for people seeking therapeutic support and for people looking to integrate insights and learnings from...
Biopharmaceutical company Cybin has selected generalised anxiety disorder (GAD), with or without major depressive disorder (MDD), as the target indication for its proprietary deuterated DMT molecule,...
Silo Pharma is advancing its clinical study exploring psilocybin’s effect on inflammation, targeting conditions such as Parkinson’s disease, bipolar disorder and chronic pain.
Irwin Naturals has signed a Letter of Intent entering into a partnership with Braxia Scientific – which is developing innovative ketamine and psilocybin treatments for mental...
Reunion Neuroscience has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug.
The first patient has been dosed in Small Pharma’s Phase I study that is comparing the profiles of the company’s proprietary formulation of DMT.